Esperion Therapeutics Inc (NASDAQ:ESPR)’s traded shares stood at 5.75 million during the last session, with the company’s beta value hitting 1.02. At the close of trading, the stock’s price was $2.21, to imply a decrease of -1.34% or -$0.03 in intraday trading. The ESPR share’s 52-week high remains $3.94, putting it -78.28% down since that peak but still an impressive 28.51% since price per share fell to its 52-week low of $1.58. The company has a valuation of $435.45M, with an average of 4.69 million shares in intraday trading volume over the past 10 days and average of 5.87 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Esperion Therapeutics Inc (ESPR), translating to a mean rating of 1.78. Of 8 analyst(s) looking at the stock, 0 analyst(s) give ESPR a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.13.
Esperion Therapeutics Inc (NASDAQ:ESPR) trade information
After registering a -1.34% downside in the last session, Esperion Therapeutics Inc (ESPR) has traded red over the past five days. The 5-day price performance for the stock is 1.84%, and -13.33% over 30 days. With these gigs, the year-to-date price performance is 0.45%. Short interest in Esperion Therapeutics Inc (NASDAQ:ESPR) saw shorts transact 32.35 million shares and set a 3.9 days time to cover.
The extremes give us $8 and $8 for target low and target high price respectively. As such, ESPR has been trading -261.99% off suggested target high and -261.99% from its likely low.
Esperion Therapeutics Inc (ESPR) estimates and forecasts
Looking at statistics comparing Esperion Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Esperion Therapeutics Inc (ESPR) shares are -19.05% down over the last 6 months, with its year-to-date growth rate higher than industry average at 86.21% against 16.30%. The rating firms project that company’s revenue will grow 180.41% compared to the previous financial year.
Revenue forecast for the current quarter as set by 9 analysts is 63.06M. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 53.3M.Earnings reports from the last fiscal year show that sales brought in 32.25M and 137.74M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 95.53% before dropping -61.30% in the following quarter.
ESPR Dividends
Esperion Therapeutics Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Esperion Therapeutics Inc (NASDAQ:ESPR)’s Major holders
Esperion Therapeutics Inc insiders hold 0.48% of total outstanding shares, with institutional holders owning 65.99% of the shares at 66.31% float percentage. In total, 65.99% institutions holds shares in the company, led by WASATCH ADVISORS LP. As of 2024-06-30, the company held over 16.86 million shares (or 9.9628% of shares), all amounting to roughly $37.44 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 13.98 million shares, or about 8.2617% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $31.04 million.
We also have Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Esperion Therapeutics Inc (ESPR) shares. Going by data provided on Sep 30, 2024 , Wasatch Ultra Growth Fund holds roughly 6.68 shares. This is just over 3.39% of the total shares, with a market valuation of $14.75 million. Data from the same date shows that the other fund manager holds a little less at 6.18, or 3.14% of the shares, all valued at about 13.66 million.
